Skin Cancer Evaluation. Simplified.

An objective, non-invasive device to assist healthcare professionals in evaluating skin cancer at the point of care.

DermaSensor Device Left
DermaSensor Device Bottom

How It Works

Assess

Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.

Analyze

Use DermaSensor to analyze those lesions of concern to receive an "Investigate Further" or "Monitor" result for each lesion.

Act

Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.

Device Application

Features

  • Simple design, effortless application
  • Non-invasive optical spectroscopy
  • Beneath the skin, cellular-level analysis
  • Objective, simple and immediate result
  • 92% sensitivity across common skin cancers1
  • 13% improvement in GPs' skin cancer detection1

DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.

David Leffell, M.D.

Chief, Section of Dermatologic Surgery and Cutaneous Oncology, Yale School of Medicine Scientific Advisory Board, DermaSensor

david lafell
David Leffell

With improved confidence in conducting skin cancer checks, you have the potential to significantly increase detection rates. Speak to one of DermaSensor's consultants today to arrange a risk-free, 30 day trial of the DermaSensor device in your practice.

Contact Us

DermaSensor looks beyond the visual to improve your decision-making and confidence.

According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.1

Lease Now

Footnotes

1Tepedino K, Tablada A, Barnes E, Da Silva, T. Clinical Utility of a Handheld Elastic Scattering Spectroscopy Tool and Machine Learning on the Diagnosis and Management of Skin Cancer by Primary Care Physicians. Poster Presentation, SDPA Fall Conference, Nov 4-7, 2021.

DermaSensor demonstrated 93% sensitivity across melanoma, BCC and SCC (95% for melanoma). DermaSensor use was found to increase physicians’ cancer detection sensitivity from 81% to 94%, and this improvement was statistically significant (p = .0009). There was no statistically significant change in the GP’s specificity, or false positive rate, for benign lesions (p = .3558).

Scroll to Top